[Prophylactic intravesical BCG for bladder tumor after surgery of upper tract urothelial carcinoma]
Related Experiment Video
Updated: Oct 21, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
T Kudoh1, F Motomura, F Saitoh
1Department of Urology, Hirosaki University School of Medicine.
Abstract:
We report the result of prophylactic intravesical instillation of BCG after surgery of upper tract urothelial carcinoma. The BCG Tokyo 172 strain was given preoperatively and/or postoperatively, as a rule, in a dose of 80 mg in 30 ml saline instilled into the bladder. Only one (14.3%) of the 7 patients with intravesical BCG developed bladder tumor at 14 month after surgery, while (45.4%) of 11 patients who did not receive intravesical BCG suffered from bladder tumor within 2 years after surgery. Prophylactic intravesical instillation of BCG reduced significantly (p less than 0.005) the recurrence of bladder tumor after the surgery of renal pelvis and ureteral tumor.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Urinary Tract Calculi III: Medical Management
Imaging Studies VI: Voiding Cystourethrography and Cystography

